Key facts
- This page summarizes Mark Germain's Form 4 filing for Scinai Immunotherapeutics Ltd. (SCNI).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 18 Jun 2026, 14:51.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Award
Additional SEC filing notes
Footnote F1
The Ordinary Shares are no par value per share, and are represented by American Depositary Shares, each of which currently represents four thousand Ordinary Shares.
Footnote F2
Includes 120,000,000 Ordinary Shares represented by restricted share units granted on June 16, 2026, which vest in three equal annual installments thereafter, subject to the Reporting Person's continued service through such dates.